Advocacy intelligence hub — real-time data for patient organizations
ROZLYTREK: FDA approved
ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
RETEVMO
Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
ROZLYTREK
(entrectinib)Orphan drugGenentech, Inc.
12.1 Mechanism of Action Entrectinib is an inhibitor of the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, and TRKC (encoded by the neurotrop...
Giles W. Robinson, MD, M.D
St. Jude Children's Research Hospital
📍 MEMPHIS, TN
Tsuyoshi Fukushima
University of Miyazaki
Fumitaka Matsumoto
University of Miyazaki
Mayumi Akaki Nagayasu
Clinical Laboratory
Hiroaki Kataoka
University of Miyazaki
Yuichiro Sato
University of Miyazaki Hospital
📍 LA JOLLA, CA